{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:29:10Z","timestamp":1791959350501,"version":"4.3.4"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Ibalizumab (formerly TNX-355) is a humanized monoclonal antibody that binds CD4, the primary receptor for human immunodeficiency virus type 1 (HIV-1), and inhibits the viral entry process. A phase lb multidose study of the safety, pharmacokinetics, and antiviral activity of ibalizumab was conducted with 22 HIV-1-infected patients. Nineteen patients were randomized to receive either 10 mg\/kg of body weight weekly (arm A) or a 10-mg\/kg loading dose followed by 6 mg\/kg every 2 weeks (arm B) intravenously for 9 weeks. Three patients were assigned to receive 25 mg\/kg every 2 weeks for five doses (arm C). During the study, the patients remained off other antiretrovirals or continued a stable failing regimen. Treatment with ibalizumab resulted in substantial reductions in HIV-1 RNA levels (0.5 to 1.7 log\n                    <jats:sub>10<\/jats:sub>\n                    ) in 20 of 22 subjects. In most patients, HIV-1 RNA fell to nadir levels after 1 to 2 weeks of treatment and then returned to baseline despite continued treatment. Baseline viral isolates were susceptible to ibalizumab in vitro, regardless of coreceptor tropism. Emerging resistance to ibalizumab was manifested by reduced maximal percent inhibition in a single-cycle HIV infectivity assay. Resistant isolates remained CD4 dependent and were susceptible to enfuvirtide in vitro. Complete coating of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell receptors was correlated with serum ibalizumab concentrations. There was no evidence of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell depletion in ibalizumab-treated patients. Ibalizumab was not immunogenic, and no serious drug-related adverse effects occurred. In conclusion, ibalizumab administered either weekly or biweekly was safe and well tolerated and demonstrated antiviral activity. Further studies with ibalizumab in combination with standard antiretroviral treatments are warranted.\n                  <\/jats:p>","DOI":"10.1128\/aac.00942-08","type":"journal-article","created":{"date-parts":[[2008,11,17]],"date-time":"2008-11-17T21:26:03Z","timestamp":1226957163000},"page":"450-457","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":146,"title":["Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults"],"prefix":"10.1128","volume":"53","author":[{"given":"Jeffrey M.","family":"Jacobson","sequence":"first","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Kuritzkes","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot","family":"Godofsky","sequence":"additional","affiliation":[{"name":"Bach and Godofsky, Bradenton, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[{"name":"IDC Research Initiative, Altamonte Springs, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Larson","sequence":"additional","affiliation":[{"name":"Tanox, Incorporated, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Weinheimer","sequence":"additional","affiliation":[{"name":"TaiMed Biologics, Inc., Bellaire, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley T.","family":"Lewis","sequence":"additional","affiliation":[{"name":"TaiMed Biologics, Inc., Bellaire, Texas"},{"name":"University of Texas Medical School\u2014Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/clin.1997.4363","volume":"84","year":"1997","unstructured":"Anderson, D., K. Chambers, N. Hanna, J. Leonard, M. Reff, R. Newman, J. Baldoni, D. Dunleavy, M. Reddy, R. Sweet, and A. Truneh. 1997. A primatized MAb to human CD4 causes receptor modulation without marked reduction in CD4+ T-cells in chimpanzees: in vitro and in vivo characterization of MAb (IDEC-CE9.1) to human CD4. Clin.l Immunol. Immunopathol.84:73-84.","journal-title":"Clin.l Immunol. Immunopathol."},{"key":"e_1_3_1_3_2","first-page":"1779","volume":"149","year":"1992","unstructured":"Burkly, L. C., D. Olson, R. Shapiro, G. Winkler, J. J. Rosa, D. W. Thomas, C. Williams, and P. Chisholm. 1992. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody: dissecting the basis for its inhibitory effect on HIV-induced cell fusion. Immunology149:1779-1787.","journal-title":"Immunology"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/135965350000500112","volume":"5","year":"2000","unstructured":"DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. Phillips, M. Ait-Khaled, J. Baxter, P. Clevenbergh, S. Hammer, R. Harrigan, D. Katzenstein, R. Lanier, M. Miller, M. Para, S. Yerly, A. Zolopa, J. Murray, A. Patick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther.5:41-48.","journal-title":"Antivir. Ther."},{"key":"e_1_3_1_5_2","first-page":"784","volume":"25","year":"1993","unstructured":"Delmonico, F. L., R. W. Knowles, R. B. Colvin, D. E. Cavender, T. Kawai, M. Bedle, D. Stroka, R. I. Preffer, C. Haug, and A. B. Cosimi. 1993. Immunosuppression of cynomolgus renal allograft recipients with humanized OKT4A monoclonal antibodies. Transplant. Proc.25:784-785.","journal-title":"Transplant. Proc."},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4734"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201023378175"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/380802"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035211"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1073\/pnas.86.11.4220","volume":"86","year":"1989","unstructured":"LoBuglio, A. F., R. H. Wheeler, J. Trang, A. Haynes, K. Rogers, E. B. Harvey, L. Sun, J. Ghrayeb, and M. B. Khazaeli. 1989. Mouse\/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA86:4220-4224.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.4049\/jimmunol.145.9.2839","volume":"145","year":"1990","unstructured":"Merkenschlager, M., D. Buck, P. C. L. Beverley, and Q. J. Sattentau. 1990. Functional epitope analysis of the human CD4 molecule. J. Immunol.145:2839-2845.","journal-title":"J. Immunol."},{"key":"e_1_3_1_13_2","unstructured":"Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1 in Europe Australia and North America: 24-week results. 2007"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2000.4975"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_3_1_16_2","first-page":"1","year":"2008","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, p.1-128. Department of Health and Human Services, Washington, DC.","journal-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1993.9.199"},{"key":"e_1_3_1_18_2","first-page":"1","volume":"13","year":"1969","unstructured":"Waldman, T. A., and W. Strober. 1969. Metabolism of immunoglobulins. Prog. Allergy13:1-110.","journal-title":"Prog. Allergy"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02006-06"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00942-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00942-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T23:55:56Z","timestamp":1684626956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00942-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1128\/AAC.00942-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00942-08","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1128874.585966","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"2008-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}